Recently, as reported in international news, the "13-OXIDIZED INGENOL DERIVATIVE AND USE THEREOF" declared by the Institute of Traditional Chinese Medicine of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited was granted an American invention patent with the patent number of US11753363B2.

This patent is independently developed by the Institute of Traditional Chinese Medicine of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited. The special project team developed a series of 13- oxidized diterpenoid alcohol ester derivatives with direct cytotoxicity and immune stimulation by using the 13- oxidized diterpenoid alcohol mother nucleus extracted from Kansui, which were used to prepare drugs for preventing and treating diseases related to proliferation or tumor formation or drugs related to symptoms in the beauty field, including skin precancerous lesions, various viral infectious skin diseases and skin cancer, etc. Compared with the listed drugs and existing natural products, they have the advantages of high efficiency and low toxicity.

The research results of the project have been applied for patents for compounds and uses in China, the United States, Europe and Australia through PCT(Patent Cooperation Treaty). In addition to the authorization of the US patent application, the applications for patents in Australia and China were granted in July 2021 and December 2022 respectively, and the European application is currently under review.

The successful authorization of this invention patent is the achievement made from the long-term attention paid by the Institute of Traditional Chinese Medicine to technological innovation. In the future, the Institute of Traditional Chinese Medicine will continue to focus on improving its independent research and development capabilities and innovation capabilities, strengthening the protection and application of intellectual property rights, giving better play to the scientific and technological functions of "two services and one guidance", and helping Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to become a leader in innovative Chinese medicine with more high-value patented technologies.